JZYY(SH:600750) KAIYUAN SECURITIES·2025-08-22 09:13Investment Rating - The investment rating for Jiangzhong Pharmaceutical is "Buy" (maintained) [1] Core Views - The company achieved a revenue of 2.141 billion yuan in H1 2025, a year-on-year decrease of 5.79%, while the net profit attributable to shareholders was 522 million yuan, an increase of 5.80% [4] - The gross margin for H1 2025 was 66.60%, down by 2.44 percentage points, and the net margin was 26.13%, up by 1.99 percentage points [4] - The company is optimistic about its long-term development potential in the gastrointestinal and related medication sectors, maintaining profit forecasts for 2025-2027 with net profits expected to be 891 million, 1.008 billion, and 1.131 billion yuan respectively [4] Financial Performance Summary - In H1 2025, the non-prescription drug business revenue was 1.550 billion yuan, down 10.14%, while the prescription drug business revenue was 360 million yuan, up 7.44% [5] - The company is focusing on digital transformation to enhance efficiency and is actively pursuing mergers and acquisitions to expand its product matrix [6] - The financial summary indicates that the company expects revenue growth of 8.7% in 2025, with a projected net profit growth of 13.0% [8]